CoChat

Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial

Open access
Aman, Michael, Rettiganti, Mallikarjuna, Nagaraja, Haikady N., Hollway, Jill A., McCracken, James, McDougle, Christopher J., Tierney, Elaine, Scahill, Lawrence, Arnold, L. Eugene, Hellings, Jessica, Posey, David J., Swiezy, Naomi B., Ghuman, Jaswinder, Grados, Marco, Shah, Bhavik, Vitiello, Benedetto · 2015 · Journal of Child and Adolescent Psychopharmacology
Cited by 89

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Risperidone has demonstrated efficacy for acute (8 week) and intermediate length (6 month) management of severe irritability and aggression in children and adolescents with autism. Less is known about the long-term effects of risperidone exposure in this population. We examined the tolerability, safety, and therapeutic benefit of risperidone exposure over a 1-2 year follow-up period. METHODS: In a naturalistic study, 84 children and adolescents 5-17 years of age (from an original sample of 101) were assessed an average of 21.4 months after initial entry into a placebo-controlled 8 week trial of risperidone for children and adolescents with autism and severe irritability. They were assessed at baseline and at follow-up on safety and tolerability measures (blood, urinalysis, electrocardiogram [ECG], medical history, vital signs, neurological symptoms, other adverse events), developmental measures (adaptive behavior, intelligence quotient [IQ]), and standardized rating instruments. Treatment over the follow-up period, after completion of protocol participation, was uncontrolled. Statistical analyses assessed outcome over time with or without prolonged risperidone therapy. RESULTS: Two-thirds of the 84 subjects continued to receive risperidone (mean 2.47 mg/day, S.D. 1.29 mg). At follow-up, risperidone was associated with more enuresis, more excessive appetite, and more weight gain, but not more adverse neurological effects. No clinically significant events were noted on blood counts, chemistries, urinalysis, ECG, or interim medical history. Regardless of drug condition at follow-up, there was considerable improvement in maladaptive behavior compared with baseline, including core symptoms associated with autism. Height and weight gains were elevated with risperidone. Social skills on Vineland Adaptive Behavior Scale (VABS) improved with risperidone. Parent-rated Aberrant Behavior Checklist (ABC) Irritability subscale scores were reduced in those taking risperidone at follow-up. Several other measures of maladaptive behavior (some related to socialization) also showed improved functioning in association with risperidone on the ABC or on the Modified Real Life Rating Scale. CONCLUSIONS: Increased appetite, weight gain, and enuresis are risks associated with long-term risperidone. Our data suggest that these risks were balanced by longer-term behavioral and social benefits for many children over 1.8 years of ongoing treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/cap.2015.0005

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 34

  1. 10.1089/cap.2005.15.869 · DOI · Paper page
  2. Aman MG, 1985, Am J Ment Deficiency, 89, 485
  3. Aman MG, 1985, Am J Mental Deficiency, 89, 492
  4. Aman MG, 1987, Am J Ment Deficiency, 92, 237
  5. American Psychiatric Association, 2000, Diagnostic and Statistical Manual of Mental Disorders
  6. 10.1023/A:1005451304303 · DOI
  7. Bozkurt H, 2011, Arch Neuropsychiatry, 48, 164
  8. 10.1097/00004583-199706000-00022 · DOI · Paper page
  9. 10.1037/0033-2909.112.1.155 · doi:10.1037/0033-2909.112.1.155 · Paper page
  10. 10.1089/cap.2011.0071 · doi:10.1089/cap.2011.0071
  11. 10.1016/S0002-7138(09)60610-5 · DOI
  12. Ghanizadeh A, 2008, Prim Psychiatry, 15, 32
  13. 10.1097/01.CHI.0000046842.56865.EC · DOI
  14. 10.1097/01.CHI.0000046841.56865.37 · DOI
  15. 10.1358/dot.2003.39.7.799445 · DOI · Paper page
  16. 10.1080/19315864.2010.494763 · DOI
  17. 10.1089/cap.2006.0056 · DOI
  18. 10.1089/cap.2012.0058 · DOI
  19. 10.1177/0883073810382143 · DOI · Paper page
  20. 10.1007/BF02172145 · DOI · Paper page
  21. 10.1089/cap.2011.0015 · DOI · Paper page
  22. 10.4088/JCP.09m05933 · DOI · Paper page
  23. 10.1176/appi.ajp.161.6.1125 · DOI · Paper page
  24. McCracken JT, 2005, J Clin Psychiatry, 66, 32
  25. 10.1176/appi.ajp.162.6.1142 · DOI · Paper page
  26. 10.1007/BF00916506 · DOI
  27. National Institute of Mental Health, 1985, Psychopharmacol Bull, 21, 1077
  28. 10.1097/00004583-200203000-00014 · DOI · Paper page
  29. 10.1176/appi.ajp.162.7.1361 · DOI · Paper page
  30. 10.1097/01.chi.0000220854.79144.e7 · DOI · Paper page
  31. 10.1002/mrdd.20038 · DOI · Paper page
  32. 10.1007/s10803-006-0307-7 · DOI · Paper page
  33. 10.1111/j.1600-0447.1970.tb02066.x · DOI · Paper page
  34. 10.1097/01.CHI.0000046840.90931.36 · DOI

Cited by

See all 89

Metadata

Authors
Aman, M., Rettiganti, M., Nagaraja, H. N., Hollway, J. A., McCracken, J., McDougle, C. J., Tierney, E., Scahill, L., Arnold, L. E., Hellings, J., Posey, D. J., Swiezy, N. B., Ghuman, J., Grados, M., Shah, B., & Vitiello, B.
Venue
Journal of Child and Adolescent Psychopharmacology
Published
2015-08
Volume
25
Issue
6
Pages
482-493
ISSN
  • 1044-5463 (ISSN-L)
  • 1557-8992
OpenAlex
W1758325167
Cited by
89
References
7
FWCI
4.43
Type
journal article
Language
en
Open access
green
Licence
www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial. https://app.cochat.ai/papers/10.1089/cap.2015.0005
The paper
Aman, M., Rettiganti, M., Nagaraja, H. N., Hollway, J. A., McCracken, J., McDougle, C. J., Tierney, E., Scahill, L., Arnold, L. E., Hellings, J., Posey, D. J., Swiezy, N. B., Ghuman, J., Grados, M., Shah, B., & Vitiello, B. (2015). Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2015.0005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.